Discover more near‑term opportunities with better event intelligence.
Fundz combines its own real-time funding and M&A intelligence with executive moves, hiring shifts and other company changes, weighs each signal against your ideal customer profile, and delivers a ranked daily shortlist with the context and decision maker to contact. Now it answers in Claude too: ask for today’s leads, then write the note in the same window.
Trusted by
OracleSnowflakeCloudflareLinkedInGoogleSalesforce
★★★★★4.8/5 on G2· Since 2015
Astrocyte Pharmaceuticals secures $9.5 million in Series B funding to advance Phase 2 clinical development of its breakthrough TBI and concussion therapy AST-004.
PRIVATESep 30, 2026
Amount Raised
$9.5 Million
Round Type
Series B
GrotonHealthcare
Description
Astrocyte Pharmaceuticals has successfully secured $9.5 million in a Series B funding round. The capital will be utilized to advance the Phase 2 clinical development of its innovative therapy for TBI and concussion, named AST-004. This funding will enable the company to conduct crucial trials and further validate its therapeutic approach. The investment underscores the potential impact of AST-004 in addressing significant unmet medical needs in brain injury treatment.
Company Information
Company
Astrocyte Pharmaceuticals Inc.
Location
93 SHENNECOSSETT ROAD
Groton, Massachusetts, United States
About
Astrocyte Pharmaceuticals is a drug discovery and development company dedicated to accelerating the recovery and well-being of brain injury patients. Astrocyte is committed to proving the neuroprotective benefits of enhanced mitochondrial energy production in astrocytes, and advancing breakthrough therapeutic agents for treating brain injury resulting from stroke, TBI, concussion, and neurodegenerative disorders such as Alzheimer’s disease.
Fundz sees it the moment Astrocyte Pharmaceuticals Inc. raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
GrotonHealthcare